(DERM) Journey Medical - Ratings and Ratios
Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US48115J1097
DERM: Medicated Wipes, Oral Medications, Topical Creams, Antifungal Solutions
Journey Medical Corporation (NASDAQ:DERM) specializes in developing and commercializing pharmaceutical products for treating dermatological conditions in the U.S. Their portfolio includes Qbrexza, a medicated cloth for primary axillary hyperhidrosis; Accutane, an oral isotretinoin for severe acne; and Amzeeq, a topical minocycline for moderate to severe acne. They also offer Zilxi for rosacea, Exelderm as an antifungal, Targadox for acne, and Luxamend for wound care. Additionally, they provide sulconazole nitrate for fungal infections and doxycycline hyclate for acne. Formerly Coronado Dermatology, Inc., the company was renamed Journey Medical Corporation and is a subsidiary of Fortress Biotech, Inc., headquartered in Scottsdale, Arizona since 2014.
As a subsidiary of Fortress Biotech, Journey Medical Corp benefits from strategic resources and research capabilities, enhancing its product pipeline and market reach. Their focus on dermatology aligns with growing demand for specialized skin treatments, supported by a diverse product range addressing various conditions.
Over the next three months, Journey Medical Corp (NASDAQ:DERM) is expected to experience volatility within a moderate range, indicated by an ATR of 0.37. The stock price, currently at 5.08, is near its 200-day SMA of 5.05, suggesting potential support. The 20-day SMA of 5.23 and 50-day SMA of 4.56 indicate a recent decline, possibly signaling a near-term bearish trend. However, the proximity to the 200-day SMA may provide support, potentially stabilizing the price or leading to a rebound.
From a fundamental perspective, the companys high forward P/E of 105.26 reflects market confidence in future growth, despite current lack of profitability. The P/B ratio of 10.10 highlights investor confidence in intangible assets or future prospects. The P/S ratio of 2.03 suggests moderate valuation relative to sales. The RoE is not available, indicating no current earnings.
The 3-month outlook suggests the stock may test the 200-day SMA support. If it holds, a rebound towards the 20-day SMA is possible. However, failure to hold support could lead to further decline. Volatility is expected to remain moderate, with price movements influenced by technical levels and potential catalysts such as earnings reports or product developments.
Additional Sources for DERM Stock
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
DERM Stock Overview
| Market Cap in USD | 175m |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| GiC Sub-Industry | Biotechnology |
| IPO / Inception | 2021-11-12 |
DERM Stock Ratings
| Growth Rating | -1.09 |
| Fundamental | -35.9 |
| Dividend Rating | 0.0 |
| Rel. Strength | 120 |
| Analysts | 4.75/5 |
| Fair Price Momentum | 6.72 USD |
| Fair Price DCF | - |
DERM Dividends
No Dividends PaidDERM Growth Ratios
| Growth Correlation 3m | 88.3% |
| Growth Correlation 12m | 38.4% |
| Growth Correlation 5y | 30.8% |
| CAGR 5y | -9.92% |
| CAGR/Max DD 5y | -0.11 |
| Sharpe Ratio 12m | -0.06 |
| Alpha | 92.15 |
| Beta | -0.564 |
| Volatility | 93.22% |
| Current Volume | 41.9k |
| Average Volume 20d | 68.1k |
As of May 09, 2025, the stock is trading at USD 6.88 with a total of 41,858 shares traded.
Over the past week, the price has changed by +0.00%, over one month by +12.79%, over three months by +31.30% and over the past year by +92.72%.
Probably not. Based on ValueRay Fundamental Analyses, Journey Medical (NASDAQ:DERM) is currently (May 2025) not a good stock to buy. It has a ValueRay Fundamental Rating of -35.94 and therefor a somewhat negative outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of DERM as of May 2025 is 6.72. This means that DERM is currently overvalued and has a potential downside of -2.33%.
Journey Medical has received a consensus analysts rating of 4.75. Therefor, it is recommend to buy DERM.
- Strong Buy: 3
- Buy: 1
- Hold: 0
- Sell: 0
- Strong Sell: 0
According to ValueRays Forecast Model, DERM Journey Medical will be worth about 7.3 in May 2026. The stock is currently trading at 6.88. This means that the stock has a potential upside of +5.38%.
| Issuer | Forecast | Upside |
|---|---|---|
| Wallstreet Target Price | 9.9 | 43.6% |
| Analysts Target Price | 9.9 | 43.6% |
| ValueRay Target Price | 7.3 | 5.4% |